Clinical applications of positron emission tomography/computed tomography treatment planning.
Positron emission tomography/computed tomography (PET/CT) has provided an incremental dimension to the management of cancer patients by allowing the incorporation of important molecular images in radiotherapy treatment planning, ie, direct evaluation of tumor metabolism, cell proliferation, apoptosis, hypoxia, and angiogenesis. The CT component allows 4D imaging techniques, allowing improvements in the accuracy of treatment delivery by compensating for tumor/normal organ motion, improving PET quantification, and correcting PET and CT image misregistration. The combination of PET and CT in a single imaging system to obtain a fused anatomical and functional image data is now emerging as a promising tool in radiotherapy departments for improved delineation of tumor volumes and optimization of treatment plans. PET has the potential to improve radiotherapy planning by minimizing unnecessary irradiation of normal tissues and by reducing the risk of geographic miss. PET influences treatment planning in a high proportion of cases and therefore radiotherapy dose escalation without PET may be futile. This article examines the increasing role of hybrid PET/CT imaging techniques in process of improving treatment planning in oncology with emphasis on non small cell lung cancer.
Macapinlac
Homer A
HA
Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. hmacapinlac@di.mdacc.tmc.edu
D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D021621:Imaging, Three-Dimensional; D008175:Lung Neoplasms / Q000532:radiotherapy; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18